Exploring gene silencing mechanisms for improved RNAi therapeutics
RNA interference (RNAi) therapeutics have garnered significant attention in clinical research due to their potential for treating various diseases, including genetic disorders, viral infections and...
View ArticleResearchers discover how a workhorse protein keeps protein production on track
Cells produce proteins like little factories. But if they make too much at the wrong times it can lead to diseases like cancer, so they control production with a process called RNA interference (RNAi).
View ArticlePlant-derived siRNAs could bring a 'green revolution' in RNAi tools and...
"Green revolution" in the early 1950s, the extensive cultivation of Dwarf Rice solves the food problem in developing countries. At present, chronic infection with hepatitis B virus (HBV) has been a...
View ArticleApplication of various nanoparticle-capsulated siRNA as therapeutics for...
In a review published in the International Journal of Molecular Sciences, researchers have been reviewing the use of siRNAs to target coronaviruses.
View ArticleRBSC announces partnership with Mitacs to develop and test yeast-based RNAi...
Renaissance BioScience Corp., a leading global microorganism bioengineering company, is pleased to announce a new partnership with Mitacs, the University of British Columbia and the University of...
View ArticleAlnylam announces positive results from Phase 1/2 study of lumasiran for...
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously...
View ArticleAlnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products...
View ArticleAlnylam reports further progress on broadening the therapeutic potential of RNAi
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today further progress on the Company's platform efforts in extrahepatic delivery of novel siRNA conjugates, including...
View ArticleAlnylam announces positive results from Phase 3 Study of givosiran for...
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational...
View ArticleEC grants marketing authorization for ONPATTRO (patisiran) in Europe
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the European Commission (EC) has granted marketing authorization for ONPATTRO (patisiran) for the treatment of...
View ArticleAlnylam’s patisiran receives positive opinion from CHMP for treating hATTR...
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the Committee for Medicinal Products for Human Use has adopted a Positive Opinion recommending marketing...
View ArticleAlnylam announces new positive results from Phase 1/2 study of lumasiran in...
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting...
View ArticleAlnylam achieves delivery of novel siRNAs conjugates to the central nervous...
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the Company has achieved delivery of novel small interfering RNA conjugates to the central nervous system and...
View ArticleRegeneron forms consortium to accelerate largest widely-available human...
By the end of 2019, Regeneron plans to sequence the exomes of all 500,000 people within the UK Biobank resource, all with associated health records, creating an unprecedented resource linking human...
View ArticleAlnylam reports new results from investigational RNAi therapeutic programs
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today preliminary results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and...
View ArticleAlnylam presents positive ongoing phase 2 open-label extension data for...
Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting...
View ArticleTrends, R&D progress, and predicted revenues in RNAi therapies
When will RNAi therapies reach the market? Visiongain's brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.
View ArticleAlnylam presents positive Phase 1 ALN-AT3 trial results in hemophilia at ISTH...
Additional study results from 12 hemophilia A and B subjects demonstrated that subcutaneous administration of ALN-AT3 achieved potent and dose-dependent knockdown of AT of up to 86%. AT knockdown was...
View ArticleAlnylam files clinical trial application for alpha-1 liver disease, presents...
Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2...
View Article
